M 300
Alternative Names: M-300; MST-0300Latest Information Update: 11 Apr 2024
Price :
$50 *
At a glance
- Originator Mestag Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunomodulators; Lymphotoxin beta receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 09 Apr 2024 Interim pharmacodynamics data from a preclinical studies in solid tumours released by Mestag Therapeutics
- 09 Apr 2024 Mestag Therapeutics plans a clinical trial for Solid tumours
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)